GlassScriptPhysician profile
Timothy T Shack
NPI 1821273616
$9,757.56
in general payments reported to CMS, 2019-2025
54 companies · $1,993 in 2025
The $1,993 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $505 · 2021: $1,244 · 2022: $1,653 · 2023: $1,276 · 2024: $1,966 · 2025: $1,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,234.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,049.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $771.64 | 2019-2024 | Myrbetriq, Veozah |
| Amgen INC. | $686.66 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $537.39 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $525.63 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $514.88 | 2022-2025 | |
| Abbvie INC. | $506.19 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $484.12 | 2019-2025 | |
| Abbott Laboratories | $481.59 | 2019-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $444.63 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $281.27 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Janssen Pharmaceuticals, INC | $277.24 | 2019-2022 | |
| Boston Scientific Corporation | $272.22 | 2019-2022 | |
| Exact Sciences Corporation | $242.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $232.08 | 2019-2020 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Shack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.